MedTrace Logo

Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor

NCT03603678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-12-11

No results posted yet for this study

Summary

The aim of this study in subjects with obstructive sleep apnea is to investigate pharmacodynamics, safety and tolerability after a single nasal administration of BAY2253651 and to evaluate first safety and tolerability of multiple dosing over 5 consecutive nights in OSA patients.

Conditions

  • Sleep Apnea, Obstructive

Interventions

DRUG

BAY2253651

100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally

DRUG

Placebo

Matching Placebo dosing

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2019-05-23
Completion
2019-09-02

Countries

  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603678 on ClinicalTrials.gov